Neurochemical changes following the administration of depleters of biogenic monoamines.
D000109:Acetylcholine / Q000032:analysis; D000409:Alanine / Q000032:analysis; D000818:Animals; D001224:Aspartic Acid / Q000032:analysis; D001679:Biogenic Amines / Q000032:analysis; D001923:Brain Chemistry / Q000187:drug effects*; D004298:Dopamine / Q000032:analysis; D010134:Fenclonine / Q000494:pharmacology; D005971:Glutamates / Q000032:analysis; D005998:Glycine / Q000032:analysis; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology*; D018377:Neurotransmitter Agents / Q000032:analysis*; D009638:Norepinephrine / Q000032:analysis; D051381:Rats; D012110:Reserpine / Q000494:pharmacology*; D012701:Serotonin / Q000032:analysis; D013747:Tetrabenazine / Q000494:pharmacology*; D005680:gamma-Aminobutyric Acid / Q000032:analysis
D001679:Biogenic Amines; D005971:Glutamates; D008781:Methyltyrosines; D018377:Neurotransmitter Agents; D001224:Aspartic Acid; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D012110:Reserpine; D000109:Acetylcholine; D000409:Alanine; D010134:Fenclonine; D005998:Glycine; D004298:Dopamine; D009638:Norepinephrine; D013747:Tetrabenazine